Theriva Biologics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Theriva Biologics, Inc. (TOVX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 113.40% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-08-11
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2026-03-31 was 113.40%.
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2022-06-30 was 95.00%.
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2019-03-31 was 86.00%.
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2016-03-31 was 117.00%, a 10.69% decline year-over-year.
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2025 was 107.40%, a 15.01% increase from fiscal 2024.
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 93.38%, a 3.76% increase from fiscal 2023.
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 90.00%, a 5.26% decline from fiscal 2022.
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2022 was 95.00%, a 3.26% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 113.40% 10-Q · filed 2026-08-11 | ||||
| 2026-03-31 | 113.40% 10-Q · filed 2026-05-05 | ||||
| 2025-12-31 | 107.40% 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | 107.40% 10-Q · filed 2025-11-12 | ||||
| 2025-06-30 | 107.40% 10-Q · filed 2026-08-11 | ||||
| 2024-12-31 | 93.38% 10-K · filed 2026-03-12 | ||||
| 2023-12-31 | 90.00% 10-K · filed 2025-03-06 | ||||
| 2022-12-31 | 95.00% 10-K · filed 2024-03-25 | ||||
| 2022-09-30 | 95.00% 10-Q · filed 2022-11-10 | ||||
| 2022-06-30 | 95.00% 10-Q · filed 2022-08-11 | 95.00% 10-Q · filed 2022-08-11 | |||
| 2021-12-31 | 92.00% 10-K · filed 2023-03-30 | ||||
| 2020-12-31 | 88.00% 10-K · filed 2022-03-16 | ||||
| 2019-12-31 | 84.00% 10-K · filed 2021-03-04 | ||||
| 2019-06-30 | 86.00% 10-Q · filed 2019-08-08 | ||||
| 2019-03-31 | 86.00% 10-Q · filed 2019-05-08 | ||||
| 2018-12-31 | 86.00% 10-K · filed 2020-02-20 | ||||
| 2016-03-31 | 117.00% 10-Q · filed 2017-05-04 | ||||
| 2015-09-30 | 0.00% 10-Q · filed 2015-11-05 | ||||
| 2015-03-31 | 131.00% 10-Q · filed 2016-05-05 | ||||
| 2014-03-31 | 126.00% 10-Q · filed 2015-05-11 | ||||
| 2013-12-31 | 110.00% 10-K · filed 2015-03-16 | ||||
| 2013-09-30 | 0.00% 10-Q · filed 2014-11-14 | 148.00% 10-Q · filed 2014-11-14 | |||
| 2013-06-30 | 0.00% 10-Q · filed 2014-08-14 | 148.00% 10-Q · filed 2014-08-14 | |||
| 2013-03-31 | 148.00% 10-Q · filed 2014-05-15 | ||||
| 2012-12-31 | 174.00% 10-K · filed 2015-03-16 | 110.00% 10-K · filed 2013-04-16 | |||
| 2012-09-30 | 153.00% 10-Q · filed 2013-11-14 | ||||
| 2012-06-30 | 171.00% 10-Q · filed 2013-08-14 | ||||
| 2011-12-31 | 174.00% 10-K · filed 2013-04-16 | ||||
| 2011-06-30 | 184.00% 10-Q/A · filed 2012-09-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |